aTYR PHARMA (ATYR) Cash & Current Investments (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Cash & Current Investments data on file, last reported at $66.5 million in Q1 2026.

• Quarterly Cash & Current Investments fell 12.88% year-over-year to $66.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.5 million (down 12.88% YoY) and the FY2025 annual result came in at $78.7 million, up 9.1% from the prior year.
• Cash & Current Investments retreated to $66.5 million in Q1 2026, from $78.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $114.4 million in Q1 2023 to a low of $66.0 million in Q3 2024.
• A 5-year average of $85.1 million and a median of $80.3 million in 2025 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 100.98% in 2022, down 38.7% in 2022.
• Tracing ATYR's Cash & Current Investments over 5 years: stood at $66.1 million in 2022, then jumped by 48.41% to $98.2 million in 2023, then slipped by 26.53% to $72.1 million in 2024, then advanced by 9.1% to $78.7 million in 2025, then decreased by 15.47% to $66.5 million in 2026.
• The last three Cash & Current Investments figures came in at $66.5 million (Q1 2026), $78.7 million (Q4 2025), and $90.2 million (Q3 2025), per Business Quant data.